secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kailera Therapeutics, Inc. (KLRA)
CIK:        0002096997
Form:       8-K
Filed at:   2026-05-26T20:18:46+00:00
Accession:  0001193125-26-239362
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kailera Q1 net loss $78.9M; advances obesity pipeline with Phase 3 start and positive data
--------------------------------------------------------------------------------

- Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025; R&D expenses rose to $70.9M from $10.1M.
- Cash $581.9M plus IPO proceeds of $718.8M expected to fund operations into mid-2028.
- Initiated global Phase 3 KaiNETIC program for ribupatide injection; data expected 2028.
- Positive Phase 2 oral ribupatide data: mean weight loss up to 12.1% at week 26; Phase 3 trials planned for early 2027.
- Positive Phase 1 data for KAI-4729 tri-agonist: up to 16.0% weight loss at 12 weeks; Phase 1 outside China planned 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/0001193125-26-239362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-239362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer